Autismo ed infi ammazione

Titolo Rivista PNEI REVIEW
Autori/Curatori Dario Siniscalco
Anno di pubblicazione 2017 Fascicolo 2017/1 Lingua Italiano
Numero pagine 8 P. 33-40 Dimensione file 1093 KB
DOI 10.3280/PNEI2017-001004
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più clicca qui

Qui sotto puoi vedere in anteprima la prima pagina di questo articolo.

Se questo articolo ti interessa, lo puoi acquistare (e scaricare in formato pdf) seguendo le facili indicazioni per acquistare il download credit. Acquista Download Credits per scaricare questo Articolo in formato PDF

Anteprima articolo

FrancoAngeli è membro della Publishers International Linking Association, Inc (PILA)associazione indipendente e non profit per facilitare (attraverso i servizi tecnologici implementati da CrossRef.org) l’accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche

L’autismo ed i disturbi dello spettro autistico (DSA) comprendono patologie complesse dello sviluppo neurologico caratterizzati da difetti cognitivi, dell’interazione sociale e della comunicazione, del linguaggio e problemi comportamentali. L’interazione tra fattori genetici ed ambientali è alla base di tale patologia, anche se la patogenesi non è ancora del tutto chiara. Una serie di eventi biochimici sono associati con l’autismo, così come disfunzioni immunitarie e problemi gastrointestinali. La componente infiammatoria ed immuno-mediata riveste particolare importanza nello sviluppo di questi disordini. Recenti evidenze sottolineano come il sistema molecolare degli endocannabinoidi sia alla base della disfunzione immunitaria ed infiammatoria.;

Keywords:Autismo, endocannabinoidi, neuro-immunomodulazione

  1. Al-Ayadhi LY e Mostafa GA (2013) Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children, J Neuroinflammation 10:72. doi.org/10.1186/1742-2094-10-72
  2. Agudelo M, Newton C, Widen R, et al. (2008) Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murinepurified B lymphocytes, J Neuroimm Pharmacol 3(1):35-42. doi.org/10.1007/s11481-007-9088-9
  3. Ashwood P, Wills S e Van de Water J (2006) The immune response in autism: A new frontier for autism research, J Leukocyte Biol 80(1):1-15. doi.org/10.1189/jlb.1205707
  4. Basu S e Dittel BN (2011) Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease, Immun Res 51(1):26-38. doi.org/10.1007/s12026-011-8210-5
  5. Buescher AV, Cidav Z, Knapp M, et al. (2014) Costs of autism spectrum disorders in the United Kingdom and the United States, JAMA Pediatr 168(8):72172-72178. doi.org/10.1001/jamapediatrics.2014.210
  6. Cencioni MT, Chiurchiù V, Catanzaro G, et al. (2010) Anandamide suppressesproliferation and cytokine release from primary human T-lymphocytesmainly via CB2 receptors, PLoS One 5(1):e8688. doi.org/10.1371/journal.pone.0008688
  7. Christensen DL, Baio J, Van Naarden Braun K, et al. (2016) Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012, MMWR Surveill Summ 65(3):1-23. doi.org/10.15585/mmwr.ss6503a1
  8. De Theije CG, Wopereis H, Ramadan M, et al. (2014) Altered gut microbiota and activity in a murine model of autism spectrum disorders, Brain Behav Immun 37:197-206. doi.org/10.1016/j.bbi.2013.12.005
  9. Enstrom AM, Onore CE, Van de Water JA, et al. (2010) Differential monocyte responses to TLR ligands in children with autism spectrum disorders, Brain Behav Immun 24(1):64-71. doi.org/10.1016/j.bbi.2009.08.001
  10. Földy C, Malenka RC e Südhof TC (2013) Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling, Neuron 78(3):498-509. doi.org/10.1016/j.neuron.2013.02.036
  11. Garbett K, Ebert PJ, Mitchell A et al. (2008) Immune transcriptome alterations in the temporal cortex of subjects with autism, Neurobiol Dis 30(3):303-311. doi.org/10.1016/j.nbd.2008.01.012
  12. Gottfried C, Bambini-Junior V, Francis F, et al. (2015) The Impact of Neuroimmune Alterations in Autism Spectrum Disorder, Front Psychiatry 6:121. doi.org/10.3389/fpsyt.2015.00121
  13. Gupta S, Samra D e Agrawal S (2010) Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin, J Clin Immunol 30:S90-S96. doi.org/10.1007/s10875-010-9402-9
  14. Hume DA (2008) Macrophages as APC and the dendritic cell myth, J Immunol 181:5829-5835. doi.org/10.4049/jimmunol.181.9.5829
  15. Ishiguro H, Horiuchi Y, Ishikawa M, et al. (2010) Brain cannabinoid CB2 receptor in schizophrenia, Biol Psych 67(10):974-982. doi.org/10.1016/j.biopsych.2009.09.024
  16. Jean-Gilles L, Gran B e Constantinescu CS (2010) Interaction between cytokines, cannabinoids and the nervous system, Immunobiology 215(8):606-610. doi.org/10.1016/j.imbio.2009.12.006
  17. Li X, Chauhan A, Sheikh AM, et al. (2009) Elevated immune response in the brain of autistic patients, J Neuroimmunol 207(1–2):111-116. doi.org/10.1016/j.jneuroim.2008
  18. Meltzer A e Van de Water J (2017) The Role of the Immune System in Autism Spectrum Disorder, Neuropsychopharmacology 42(1):284-298. doi.org/10.1038/npp.2016.158
  19. Molloy CA, Morrow AL, Meinzen-Derr J, et al. (2006) Elevated cytokine levels in children with autism spectrum disorder, J Neuroimmunol 172(1-2):198-205. doi.org/10.1016/j.jneuroim.2005.11.007
  20. Robinson SA, Loiacono RE, Christopoulos A, et al. (2010) The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling, Brain Res 1343:153-167. doi.org/10.1016/j.brainres.2010.04.031
  21. Schneider M e Koch M (2005) Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: Effects of chronic pubertal cannabinoid treatment, Neuropsychopharmacology 30(5):944-957. doi.org/10.1038/sj.npp.1300634
  22. Schultz ST (2010) Can autism be triggered by acetaminophen activation of the endocannabinoid system?, Acta Neurobiol Exp (Wars) 70(2):227-231.
  23. Schultz ST e Gould GG (2016) Acetaminophen Use for Fever in Children Associated with Autism Spectrum Disorder, Autism Open Access 6(2):170. doi.org/10.4172/2165-7890.1000170
  24. Servadio M, Melancia F, Manduca A, et al. (2016) Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid, Transl Psychiatry 6(9):e902. doi.org/10.1038/tp.2016.182
  25. Siniscalco D, Sapone A, Cirillo A, et al. (2012a) Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?, J Biomed Biotechnol 2012:480289. doi.org/10.1155/2012/480289
  26. Siniscalco D, Sapone A, Giordano C, et al. (2012b) The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients, J Autism Dev Disord 42(7):1403-1410. doi.org/10.1007/s10803-011-1373-z
  27. Siniscalco D, Di Marsilio A e Antonucci N (2013a) Ethics in Autism Care, Autism 3:e119. doi.org/10.4172/2165-7890.1000e119
  28. Siniscalco D, Cirillo A, Bradstreet JJ, et al. (2013b) Epigenetic findings in autism: new perspectives for therapy, Int J Environ Res Public Health 10(9):4261-4273. doi.org/10.3390/ijerph10094261
  29. Siniscalco D, Sapone A, Giordano C, et al. (2013c) Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders, J Autism Dev Disord 43(11):2686-2695. doi.org/10.1007/s10803-013-1824-9
  30. Siniscalco D e Antonucci N (2014) Role of proteases in autism spectrum disorders, in: Chakraborti S e Dhalla NS (eds) 2014, Proteases in Health and Disease, Springer Science, New York, pp.327-333.
  31. Siniscalco D, Antonucci N, Maione S, et al. (2014a) Receptor/regulatory molecules pattern changes: caspases in autism spectrum disorders, in: Patel VB, Preedy VR e Martin CR (eds) 2014, A comprehensive guide to autism. Biochemical aspects in autism spectrum disorders, Springer-Verlag, New York, pp. 1245-1257.
  32. Siniscalco D (2014b) Endocannabinoid System as Novel Therapeutic Target for Autism Treatment, Autism Open Access 4:e122. doi.org/10.4172/2165-7890.1000e122
  33. Siniscalco D (2014c) Adhesion G-protein Coupled Receptors in Autism, Autism-Open Access 4:e126. doi.org/10.4172/2165-7890.1000e126
  34. Siniscalco D, Bradstreet JJ, Cirillo A, et al. (2014d) The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages, J Neuroinflammation 11:78. doi.org/10.1186/1742-2094-11-78

Dario Siniscalco, Autismo ed infi ammazione in "PNEI REVIEW" 1/2017, pp 33-40, DOI: 10.3280/PNEI2017-001004